[Ad hoc announcement pursuant to Art. 53 LR] Roche provides update on Phase III GRADUATE programme evaluating gantenerumab in early Alzheimer’s diseaseRoche - Nov 14, 2022
Update on the DIAN-TU-001 Trial with E2814 and Investigational Lecanemab (Eisai Co., Ltd)
The statement below is in response to the 28 September 2022 announcement found on Eisai’s website. Eisai Co., Ltd. (Headquarters:...